Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucrictibant for HAE Prophylaxis (CHAPTER-3)
NCT06669754Phase 3Active, not recruiting
- Sponsor
- Pharvaris
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Countries
- 24
01
Overview
A Phase 3 trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Started Dec 2024; status: active, not recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06669754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669754.